Torrent Pharmaceuticals Ltd
TORNTPHARMTorrent Pharmaceuticals Ltd
TORNTPHARMPrice Chart
Scorecard
Performance
AvgPrice return has been average, nothing exciting
Valuation
HighSeems to be overvalued vs the market average
Growth
LowLagging behind the market in financials growth
Profitability
HighShowing good signs of profitability & efficiency
Entry point
AvgThe stock is overpriced but is not in the overbought zone
Red flags
LowNo red flag found
How to use scorecard? Learn more
Key Metrics
No LabelNo Label | PB RatioPB Ratio | Dividend YieldDiv. Yield |
---|---|---|
60.86 | 14.67 | 0.82% |
Sector PESector PE | Sector PBSector PB | Sector Div YldSctr Div Yld |
---|---|---|
51.72 | 5.89 | 0.55% |
Forecast & Ratings
Detailed Forecastfrom 26 analysts
Price
Price Upside
Earnings
Earnings Growth
Revenue
Rev. Growth
Company Profile
Torrent Pharmaceuticals Limited is engaged in the manufacture and sale of branded, as well as unbranded generic pharmaceutical products.
Investor Presentation
View olderPeers
Compare with peersSun Pharmaceutical Industries Ltd
Cipla Ltd
Dr Reddy's Laboratories Ltd
Mankind Pharma Ltd
Zydus Lifesciences Ltd
Get more out of Tickertape, Go Pro!
Customise key metrics, see detailed forecasts, download stock data and more
Forecasts
Price
Revenue
Earnings
Price Forecast
All values in ₹
All values in ₹
Revenue Forecast
All values in ₹ Thousand cr.
All values in ₹ Thousand cr.
Earnings Per Share Forecast
All values in ₹
All values in ₹
Income
Balance Sheet
Cash Flow
Income Statement
Financial Year | FY 2015 | FY 2016 | FY 2017 | FY 2018 | FY 2019 | FY 2020 | FY 2021 | FY 2022 | FY 2023 | TTM | ||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Total Revenue | 4,939.00 | 6,912.50 | 6,038.99 | 6,248.67 | 7,729.85 | 8,060.61 | 8,061.48 | 8,704.60 | 9,665.29 | 10,598.00 | ||||||||||
Raw Materials | 1,475.71 | 1,725.04 | 1,931.39 | 2,035.67 | 2,136.25 | 2,300.05 | 2,425.66 | 2,368.15 | 2,569.00 | 7,262.00 | ||||||||||
Power & Fuel Cost | 97.41 | 92.59 | 107.98 | 118.77 | 132.46 | 128.19 | 122.94 | 144.19 | 155.28 | |||||||||||
Employee Cost | 841.81 | 842.35 | 993.41 | 1,135.25 | 1,403.79 | 1,429.04 | 1,439.62 | 1,526.45 | 1,677.69 | |||||||||||
Selling & Administrative Expenses | 1,004.31 | 847.92 | 964.14 | 1,084.65 | 1,299.49 | 1,317.15 | 1,155.10 | 1,278.57 | 1,502.70 | |||||||||||
Operating & Other expenses | 214.05 | 639.63 | 441.50 | 226.24 | 1,074.76 | 594.52 | 381.17 | 1,244.11 | 873.43 | |||||||||||
EBITDA | 1,305.71 | 2,764.97 | 1,600.57 | 1,648.09 | 1,683.10 | 2,291.66 | 2,536.99 | 2,143.13 | 2,887.19 | 3,336.00 | ||||||||||
Depreciation/Amortization | 190.74 | 237.55 | 306.92 | 408.60 | 617.69 | 654.38 | 657.79 | 662.16 | 706.59 | 801.00 | ||||||||||
PBIT | 1,114.97 | 2,527.42 | 1,293.65 | 1,239.49 | 1,065.41 | 1,637.28 | 1,879.20 | 1,480.97 | 2,180.60 | 2,535.00 | ||||||||||
Interest & Other Items | 175.16 | 183.98 | 205.56 | 308.48 | 503.75 | 450.71 | 352.94 | 255.06 | 333.44 | 381.00 | ||||||||||
PBT | 939.81 | 2,343.44 | 1,088.09 | 931.01 | 561.66 | 1,186.57 | 1,526.26 | 1,225.91 | 1,847.16 | 2,154.00 | ||||||||||
Taxes & Other Items | 188.87 | 610.20 | 154.54 | 252.90 | 125.38 | 161.85 | 274.38 | 448.73 | 601.93 | 660.00 | ||||||||||
Net Income | 750.94 | 1,733.24 | 933.55 | 678.11 | 436.28 | 1,024.72 | 1,251.88 | 777.18 | 1,245.23 | 1,494.00 | ||||||||||
EPS | 22.19 | 51.21 | 27.58 | 20.03 | 12.89 | 30.28 | 36.99 | 22.96 | 36.79 | 44.14 | ||||||||||
DPS | 5.63 | 17.50 | 7.00 | 7.00 | 8.50 | 16.00 | 17.50 | 24.00 | 22.00 | 22.00 | ||||||||||
Payout ratio | 0.25 | 0.34 | 0.25 | 0.35 | 0.66 | 0.53 | 0.47 | 1.05 | 0.60 | 0.50 |
Company Updates
Annual report
PDFAnnual report
PDFAnnual report
PDFInvestor Presentation
Peers & Comparison
Health CarePharmaceuticals
Valuation
Technical
Forecast
Stock | PE RatioPE Ratio | PB RatioPB Ratio | Div. YieldDividend Yield |
---|---|---|---|
Torrent Pharmaceuticals Ltd | 73.02 | 14.67 | 0.82% |
Sun Pharmaceutical Industries Ltd | 42.07 | 6.01 | 0.77% |
Cipla Ltd | 40.29 | 4.76 | 0.61% |
Dr Reddy's Laboratories Ltd | 21.99 | 4.26 | 0.67% |
Price Comparison
Compare TORNTPHARM with any stock or ETFShareholdings
Promoter Holdings Trend
Total Promoter Holding
In last 6 months, promoter holding in the company has almost stayed constant
Low Pledged Promoter Holding
Pledged promoter holdings is insignificant
Institutional Holdings Trend
Total Retail Holding
In last 3 months, retail holding in the company has almost stayed constant
Foreign Institutional Holding
In last 3 months, foreign institutional holding of the company has almost stayed constant
Shareholding Pattern
Jun 2023
Sep 2023
Dec 2023
Mar 2024
Shareholding History
Mutual Funds Holding Trend
Mutual Fund Holding
In last 3 months, mutual fund holding of the company has almost stayed constant
Top 5 Mutual Funds holding Torrent Pharmaceuticals Ltd
Funds (Top 5) | The rupee value of the stock held by the fund divided by the stock’s market cap Market-cap held | Percentage of the fund’s portfolio invested in the stock Weight | Change in the portfolio weight of the stock over the last 3 months 3M holding change | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months Portfolio rank(3M change) |
---|---|---|---|---|
KOTAK EMERGING EQUITY SCHEME - DIRECT PLAN - GROWTH Growth | The rupee value of the stock held by the fund divided by the stock’s market cap 0.6605% | Percentage of the fund’s portfolio invested in the stock 1.51% | Change in the portfolio weight of the stock over the last 3 months -0.13% | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months 17/90 (0) |
UTI Flexi Cap Fund - Growth - Direct Plan Growth | The rupee value of the stock held by the fund divided by the stock’s market cap 0.3314% | Percentage of the fund’s portfolio invested in the stock 1.23% | Change in the portfolio weight of the stock over the last 3 months 0.13% | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months 37/67 (+7) |
Nippon India PHARMA FUND DIRECT PLAN GROWTH PLAN - GROWTH OPTION GROWTH Growth | The rupee value of the stock held by the fund divided by the stock’s market cap 0.1726% | Percentage of the fund’s portfolio invested in the stock 2.20% | Change in the portfolio weight of the stock over the last 3 months 0.05% | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months 20/36 (+1) |
Compare 3-month MF holding change on Screener
smallcases
Looks like this stock is not in any smallcase yet.
Events
Dividend Trend
No Trend In Dividends
TORNTPHARM has shown inconsistent dividend trend over the last 5 years
Dividend Yield
Current dividend yield is 0.82%. An investment of ₹1,000 in the stock is expected to generate dividend of ₹8.19 every year
Dividends
Corp. Actions
Announcements
Legal Orders
Upcoming Dividends
No upcoming dividends are available
Past Dividends
Cash Dividend
Ex DateEx DateFeb 12, 2024
Dividend/Share
₹22.00
Ex DateEx Date
Feb 12, 2024
Cash Dividend
Ex DateEx DateJun 23, 2023
Dividend/Share
₹8.00
Ex DateEx Date
Jun 23, 2023
Cash Dividend
Ex DateEx DateFeb 3, 2023
Dividend/Share
₹14.00
Ex DateEx Date
Feb 3, 2023
Cash Dividend
Ex DateEx DateJun 3, 2022
Dividend/Share
₹15.00
Ex DateEx Date
Jun 3, 2022
Cash Dividend
Ex DateEx DateJun 3, 2022
Dividend/Share
₹8.00
Ex DateEx Date
Jun 3, 2022
News & Opinions
New buy signal generated in these 4 F&0 scrips as per RMI scanner
3 weeks ago•Moneycontrol
Torrent Pharma Q3 Results Review - Strong Performance Across Branded Markets: Nirmal Bang
2 months ago•Bloomberg Quint
Buy Torrent Pharmaceuticals; target of Rs 2700: Sharekhan
3 months ago•Moneycontrol
News Video
Torrent Pharma Withdraws Plan To Buy Founders Stake In Cipla
4 months ago•ET NOW
U.S. regulator inspects Indian pharma firms
4 months ago•The Hindu
Torrent Pharma Q2 Results Review: Analysts See Steady Growth In India Business
6 months ago•Bloomberg Quint
Stocks to Watch: Axis Bank, Tech M, Vedanta, Delta Corp, ONGC, Torrent Pharma, and Others - News18
6 months ago•News18
Higher than Industry Revenue Growth
Over the last 5 years, revenue has grown at a yearly rate of 9.12%, vs industry avg of 8.36%
Decreasing Market Share
Over the last 5 years, market share decreased from 3.08% to 2.96%
Higher than Industry Net Income
Over the last 5 years, net income has grown at a yearly rate of 12.92%, vs industry avg of 9.82%